Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Multi4 - the first surgical instrument for bladder cancer treatment through a 20-minute outpatient procedure

Descripción del proyecto

Nuevo tratamiento para el cáncer de vejiga

Cada año se diagnostica cáncer de vejiga (CV) a unos ciento setenta y cinco mil europeos, lo que lo convierte en el quinto cáncer más frecuente en la Unión Europea. El proceso de diagnóstico del CV es complejo y requiere mucho tiempo, mientras que su tratamiento se basa en operaciones de resectoscopia peligrosas y anticuadas, que conllevan un riesgo sustancial de recidiva. En este contexto, el proyecto Multi4, financiado con fondos europeos, pretende desarrollar el revolucionario dispositivo y plataforma Multi4. Esta innovación permite el tratamiento localizado del CV mediante cistoscopia adaptable durante la consulta inicial con el urólogo. Sus funciones diversas van desde la anestesia localizada hasta la extirpación de crecimientos cancerosos, todo ello en un plazo de viente minutos. La innovadora tecnología Multi4 y su expansión podrían beneficiar a cientos de miles de pacientes.

Objetivo

Bladder Cancer (BC) is the 5th most common cancer in Europe with the incidence of 175.000 cases annually and has the highest lifetime treatment cost of all cancers. At the diagnostic step, a cystoscope is used. Usually, no biopsies are taken as there are no efficient methods to do so in the outpatient care. If the patient has suspected cancer seen on the monitor, they are scheduled for a surgery. At the surgery step, the biopsies are taken and the cancer is removed using a resectoscope. The procedure is difficult to perform. The instrument used is hard (metal, up to 12 mm in diameter) and inflexible (can damage the urethra). There is a high risk of cancer reseeding elsewhere in the bladder. Up to 75 % of BC patients relapse within 5 years. The related costs in the EU are estimated at € 5 billion annually. No development has taken place since the 1960 when the existing instruments were developed.

We have developed and patented the first medical device (called Multi4) which allows for local treatment of BC through flexible cystoscopy during one visit to the urologist. The instrument has 4 functions:

1. Inject local anaesthesia through a thin needle
2. Pieces of the cancer are cut by the specially coated forceps. Bleeding is stopped immediately.
3. The cancer tissue is automatically transported out through the instrument itself.
4. When the forceps are closed, they become a burning electrode used to burn the surface where the cancer was located and ensure that all cancer cells have been killed.

With the Multi4 platform, the patient can have their cancer treated at the first visit to the urologist. The procedure takes 20 minutes. This technology can thus disrupt the existing healthcare pathways where BC is treated through expensive and complicated surgeries.
The proposed project will develop a go-to-market strategy for this ground-breaking deep tech innovation and empower the female founder to scale the company.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIE-2022-SCALEUP-02

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

MULTI4 MEDICAL AB
Aportación neta de la UEn
€ 75 000,00
Dirección
BACKALYCKEVAGEN 15
553 13 Jonkoping
Suecia
Pyme
Sí
Región
Södra Sverige Småland med öarna Jönköpings län
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos